MedTrace Logo

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

NCT04788043 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-06-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.

Conditions

  • Hodgkin Lymphoma
  • Classic Hodgkin Lymphoma
  • Relapsed Classical Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma

Interventions

PROCEDURE

PET/CT

Scan

DRUG

Magrolimab

45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion

DRUG

Pembrolizumab

200 mg IV infusion

Sponsors & Collaborators

Principal Investigators

  • Ranjana H Advani, MD · Stanford Universiy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-21
Primary Completion
2024-10-11
Completion
2025-08-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788043 on ClinicalTrials.gov